搜索
,(,200032):,CMF;,,CMF,CMF:;;:R737.9:A:100028225(2002)0220129203:(19722),,,,(goserelin,zo2ladex)(LHRH2a),,1,,(LH)(FSH),,,,(LHRH),LHFSH,FSHLH,,,,2,25g/kg1000g/kg,6(17),,510,410,10%,30%,(57),43%,17%,90%,250g/kg,8L/h,45,,,,,,2414LD50400mg/kg,2414LD50200mg/kg;,2414LD5059mg/kg56mg/kg,2414LD5030mg/kg40mg/kg,,1000gkg-1d-1,3000gkg-1d-1,6,,,LHRH2a,,,,[1,2]33.1[3],3.6mg(n=6),LH1,,,92120024292,LH,LHRH,LH,LHRHLHRH,,,80.4%50,3.229[4]3.6mg228,(CR+PR)36.4%,(SD)49.6%,12(449),44(4160),(TTP)22,26.5,(ER),ERER44.1%29.9%30.6%,33.115.928.8(),33.3%,39.0%,14,3(21.4%),,,:75.9%,47.4%,2.2%,2,6,1,,3.33.3.1:[5,6]358,283.6mg1,40mg193,117.5(31%38%)(127140),(2328,P=0.03),,,(74%72%)(13%18%)(18%18%)(15%10%)(2%3%),1,3[5,6][7](3.6mg)136ER()(PR),67,69,41(29)(30),(CR+PR)31%27%,SD28%26%,24%30%,(DFS)64(HR=0.73,95%CI=0.511.04),(OS)3733(HR=0.80,95%CI=0.531.20),,,(66%43%)(16%3%)(6%3%)(9%2%)(10%6%)(6%2%)(6%3%)(3%6%),(P=0.001)(P=0.01),,,CMF40%60%,(DoR)610,Blamey3.6mg10.1,Jonat13.6,CMF,,,[8,9]3.3.2:ZEBRA,CMF[10]164015102,,:817,CMF03120024292823,3.6mg/28,2,CMF,28,6ER(P=0.0016),ERER6:ER(74%)(HR=1.01,95%CI=0.841.20,P=0.94),ERCMF(HR=1.76,95%CI=1.272.44,P=0.0006);ER(HR=1.01,95%CI=0.761.28,P=0.92),ERCMF(HR=1.77,95%CI=1.192.63,P=0.0043),,,,,,,,96(53,CMF43),2,,3,CMF,,CMF,861010(514,CMF496),,36,(P0.00001),,64,CMF,,,CMF,,[1]CockshottID.Clinicalpharmacokineticsofgoserelin[J].ClinPhar2macokinet,2000,39(1):27248.[2]LombardiP,FlorisS,PagniniU,etal.OvarianfunctionsuppcessionwithaGnRHanalogue:D2ser(But[t][6]2Arzgly[10]2LHRH(Goserelin)inhormonedependentcaninemammarycancer[J].JVetPharmacolTher,1999,22(1):56261.[3]PrichardKI.Currentandfuturedirectionsinmedicaltherapyforbreastcarcinoma:endocrinetreatment[J].Cancer,2000,88(12Sup2pl):306523072.[4]JonatW,KaufmannM,BlameyRW,etal.Arandomisedstudytocomparetheeffectoftheluteinisinghormonereleasinghormone(LHRH)analogue,goserelin,withorwithouttamoxifeninpre2andperimenopausalpatientswithadvancedbreastcancer[J].EurJCan2cer,1995,31A(2):1372142.[5]MichaudLB,BuzdarAU.Completeestrogenblockadeforthetreat2mentofmetastaticandearlystagebreastcancer[J].DrugsAging,2000,16(4):2612272.[6]NystedtM,BerglundG,BolundC,etal.Randomizedtrialofadju2vanttamoxifenand/orgoserelininpremenopausalbreastcancer2self2ratedphysiologicaleffectsandsymptoms[J].ActaOncol,2000,39(8):9592968.[7]TaylorCW,GreenSS,DaltonWS,etal.Muticenterranomisedclin2icaltrialofgoserelinversussurgicaloveriectomyinpremenopausalpa2tientswithreceptor2positivemetastaticbreastcancer[J].JClinOn2col,1998,16(3):9942999.[8]BerglundG,NystedtM,BolundC,etal.Effectofendocrinetreat2mentonsexualityinpremenopausalbreastcancerpatients:aprospec2tiverandomizedstudy[J].JClinOncol,2001,19(11):278822796.[9]FellowesD,FallowfieldLJ,SaundersCM,etal.Tolerabilityofhormonetherapiesforbreastcancer:howinformativearedocument2edsymptomprofilesinmedicalnotesforwell2toleratedtreatments[J]?BreastCancerResTreat,2001,66(1):73281.[10]JonatW.ZoladexTM(goserelin)Vs.CMFasadjuvanttherapyinpre2/perimenopausalearly(nodepositive)breastcancer:priliminaryefficacy,QOLandBMDDresultsfromtheZEBRAstudy[J].BreastCancerResTreat,2000,64(1):29(Abs13).(:2001208221:2002201218)13120024292